Dear Sir,
The two allelic forms of the angiotensin-converting enzyme (ACE) gene are characterized by the presence (I) or absence (D) of a 287 base pair repetitive DNA domain in intron 16. ACE gene insertion/ deletion (I/D) polymorphism accounts for nearly half the variance of the serum levels of the enzyme in general population. Homozygosity for the D allele (DD) of the ACE gene is the allelic variant associated with higher ACE plasma levels.
1 It is still controversial whether the ACE gene polymorphism is associated with arterial hypertension 2-3 as well as if the DD homozygosity is associated with left ventricular (LV) hypertrophy 4, 5 . High levels of plasma ACE have been found in patients with carotid wall thickening and the ACE DD genotype was found associated with significantly higher common carotid intima-media thickness (IMT) in a general population. 6 The present investigation has been designed to detect possible differences in LV anatomy and carotid arteries morphology according to ACE genotype in newly discovered hypertensive patients with stable body weight, who had never taken antihypertensive drugs.
A total of 64 patients (42 M, 22 F), 21-to 64-yearold, with newly discovered and never treated mildto-moderate arterial hypertension, entered the study. The study protocol was approved by the Ethical Committee. Resting blood pressure (BP) was measured three times at 2-week intervals using an automatic sphygmomanometer (Standard Sentron, Bard Biomedical). Body weight (w) and height (h) were also measured and body mass index (BMI ¼ kg/ m 2 ) was calculated. Patients were also asked to complete a questionnaire concerning their smoking habits. BP over 24 h was also assessed by ambulatory blood pressure monitoring (ABPM), using a Spacelabs Inc. 90207 (Redmond, WA, USA), during a normal working day, according to the procedure previously described. 7 The I/D polymorphism of the ACE gene has been investigated using a multiplex polymerase chain reaction (PCR), which has been proved a reliable and time-saving technique. 8 Two-dimensionally targeted M-mode echocardiograms were performed according to the procedure described elsewhere, 7 using an echocardiograph AU3 Partner ESAOTE Biomedica, Florence, Italy. Left ventricular mass index (LVMi) was calculated as the ratio of LV mass to height to the power 2.7 (g/m 2.7
). Carotid ultrasound imaging was performed with a Biosound Ultrasound System, 2000 II SA (Bio Dynamics, Indianapolis, IN, USA), as previously described. 9 Data are expressed as mean 7 standard deviation. Comparisons were performed by one-way analysis of variance with Tukey's multiple comparisons. The strength of the correlation between different variables was evaluated by Pearson's linear correlation. The study was planned in order to detect a significant difference of 5.76 g/m 2.7 in LV mass according to ACE genotype with alpha level ¼ 0.05 and beta level ¼ 0.1.
The frequencies of D and I alleles were 60 and 40%, respectively. In particular, 21 patients (32.8%) were DD, 35 (54.7%) were DI, and eight (12.5%) were II. Data have been analysed as DD vs non-DD (DI+II) genotype. The groups were not statistically different for age (43 7 9 vs 44 7 11 years), BMI (26.5 7 3 vs 26.8 7 3 kg/m 2 ) and BP measured both in the outpatient clinic (mean BP 116.9 7 13 vs 111.9 7 11 mmHg) and during 24 h (mean BP 105.0 7 12 vs 106.2 7 13 mmHg). Prevalence of LV hypertrophy, expressed as LVMi451 g/m 2.7 averaged 15% of the whole study-population (10/64 patients). Plasma levels of ACE were higher in the DD (43.5 7 15 U/l) than in non-DD group (27.3 7 9 U/l P ¼ 0.001). Plasma renin activity (2.4 7 2 vs 1.9 7 2 ng/ml/h) and serum aldosterone concentrations (158 7 107 vs 170 7 121 pg/ml) did not show significant difference between groups. ST (11.1 7 0.2 vs 10. Patients with D homozygosity exhibited higher values of systemic resistance (2.0 7 0.2 vs 1.6 7 0.5 dyn s/cm À5 ; p ¼ 0.05) and smaller carotid diameter (5.9 7 0.5 vs 6.5 7 0.7 mm; P ¼ 0.03) than DI+II genotype. In pooled groups, plasma ACE levels were related to peripheral resistance (r ¼ 0.370; P ¼ 0.03) and LV mass h 2.7 was related to mean BP measured either at rest (r ¼ 0.179, Po0.05) or during 24 h recording (r ¼ 0.256, Po0.002). When examined in separate genetic groups, the relation between LVMi and mean BP was confirmed in the DD genotype (r ¼ 0.735, P ¼ 0.01), but not in DI+II genotypes (r ¼ 0.144, P n.s.) (Figure 1 ).
The present study was planned to investigate the association between DD genotype of ACE-gene and end-organ damage of hypertensive patients, independently of confounding therapeutical influences. We have indeed selected patients with high BP levels detected in the last few months, with normal BP levels measured not more than 1 year before. These selection criteria strongly restricted the number of suitable patients since many of them had no information on their BP values of the previous years, others had received antihypertensive treatment from their general practitoner when hypertension was detected, others had changed their habitual diet and had experienced weight loss. The low prevalence of LV hypertrophy, which is almost half of that observed in the general hypertensive population, confirmed the recent onset of arterial hypertension in the study group. The distribution of the D/I ACE polymorphism was similar to that observed in larger populations of other studies performed in the US 5 and in Italy. 6 We have also found that homozygosity for the ACE D allele is associated with significantly higher plasma levels of ACE without evident interferences on the angiotensin-aldosterone axis. Furthermore, we have also found that the D/I polymorphism of the ACE gene does not correlate with BP levels, as already shown previously. Neverthless, DD allelic variant of the ACE gene contributed to early functional changes in the vascular district of these newly discovered hypertensives. Total peripheral resistance, in fact, was significantly increased by 25% in DD compared to non-DD genotype, the influence of the genotype being further strengthened by the significant correlation between resistance and plasma ACE levels. Not only resistance vessels but also capacitance arteries seem to be influenced by the allelic variants of ACE gene since carotid diameter was significantly reduced in the DD subgroup.
With regard to structural changes in the cardiovascular district, we did not find any difference in LV mass and IMT between the ACE gene polymorphism subgroups. The lack of differences in LV mass among genotypical subgroups may be expected at this early stage of hypertension, since the genetic component does not appear sufficiently potent to independently induce LV hypertrophy. However, the close relation between BP levels and LV mass, present only in DD genotypes, suggests that homozygosity for the ACE D allele might be a predisposing factor for the effects of pressure levels on myocardial mass.
Our data show that the DD ACE genotype favourably influences the relation between BP and LV mass or carotid wall thickness even when haemodynamic effects of pressure overload on ventricular mass and arterial wall are limited. The D/I ACE gene polymorphism, therefore, might act as a susceptibility gene for the end-organ damage in patients exposed to arterial hypertension. ) according to ACE genotype in hypertensive patients.
